PMDA SAKIGAKE Designation: Review of Approved Drugs & Impact in Japan
This article reviews the PMDA SAKIGAKE Designation, highlighting approved drugs such as XYZ for cancer treatment and its significant impact on Japan's pharmaceutical landscape.
Medically Reviewed
by Dr. James Morrison, Chief Medical Officer (MD, FACP, FACC)
Reviewed on: April 28, 2026
Key Takeaways
- System overview: The Pharmaceuticals and Medical Devices Agency (PMDA) SAKIGAKE Designation System, initiated as a pilot in 2015 and formalized in September 2020, fast-tracks the approval of innovative drugs aimed at serious diseases with unmet medical needs in Japan.
- Eligibility criteria: For SAKIGAKE designation, drugs must show novel mechanisms of action, demonstrate significant efficacy, focus on serious conditions with unmet needs, and seek their first approval in Japan.
- Early adoption impact: As of March 2020, eight drugs had received SAKIGAKE designation, highlighting the program's effectiveness in enhancing patient access and promoting pharmaceutical innovation across oncology, rare diseases, neurology, and immunology.
- Strategic importance: The SAKIGAKE designation sets Japan's regulatory pathway apart by facilitating prioritized review and consultation, making it an appealing market for first-in-market approvals and driving competitive pharmaceutical development.
The Pharmaceuticals and Medical Devices Agency (PMDA) SAKIGAKE Designation System is a regulatory initiative aimed at speeding up the approval of innovative pharmaceuticals in Japan. Launched as a pilot program in 2015 and made permanent in September 2020, the PMDA SAKIGAKE designation process prioritizes drugs with novel mechanisms addressing serious diseases and unmet medical needs. This system significantly alters Japan's drug approval process by allowing earlier patient access to new therapies and encouraging both multinational and domestic pharmaceutical companies to seek first-in-Japan approvals, thereby enhancing the country's pharmaceutical innovation ecosystem.
Understanding the SAKIGAKE Designation System
The SAKIGAKE Designation System reflects the PMDA's dedication to balancing regulatory standards with expedited access to innovative therapies. This system includes a structured framework prioritizing review processes for drugs that meet specific clinical and regulatory criteria. Originally launched as a pilot program in 2015, the designation achieved permanent status in September 2020, reinforcing Japan's commitment to fast-tracked pathways for innovative medicines.
To qualify for SAKIGAKE designation, candidate drugs must meet four essential criteria: they must demonstrate a novel mechanism of action not previously approved in Japan, target serious diseases with documented unmet medical needs, provide evidence of significant efficacy in clinical trials, and seek first approval in Japan. This requirement that the drug pursue its initial approval in the Japanese market differentiates SAKIGAKE from other global expedited pathways, positioning Japan as a priority market for pharmaceutical innovation.
As of March 2020, eight drugs have been granted SAKIGAKE designation, showcasing the program's initial success across multiple therapeutic areas, including Oncology, Rare Diseases, Neurology, and Immunology. This distribution illustrates the PMDA's commitment to addressing unmet needs across a variety of patient populations and disease categories.
Regulatory Context: PMDA's Prioritized Review Framework
The SAKIGAKE Designation System functions within Japan's broader regulatory framework, overseen by the PMDA, the primary authority for pharmaceutical and medical device approvals. This system complements existing expedited pathways, such as priority review and orphan drug designation, but uniquely emphasizes novel mechanisms and the requirement for first approval in Japan.
SAKIGAKE-designated drugs benefit from prioritized consultation with PMDA reviewers during development and expedited review timelines during the formal submission phase. This structure allows pharmaceutical sponsors to refine their development strategies according to PMDA expectations, potentially mitigating the risk of significant deficiencies in the formal application and speeding up the time to market authorization.
The stipulation that SAKIGAKE-designated drugs seek first approval in Japan provides a unique competitive edge for the Japanese pharmaceutical market. This condition encourages multinational pharmaceutical companies to prioritize Japan in their global development and regulatory strategies, potentially offering Japanese patients earlier access to innovative therapies compared to other markets. The PMDA balances this expedited review process with thorough evaluations of efficacy and safety data, ensuring the scientific and clinical standards necessary to protect public health while minimizing delays for drugs that meet serious unmet needs.
Market Impact and Strategic Implications for APAC
The eight drugs that received SAKIGAKE designation by March 2020 illustrate a diverse portfolio covering multiple therapeutic areas, indicative of the PMDA's commitment to innovation across various disease categories. The designation's influence extends beyond single drug approvals, affecting the broader pharmaceutical landscape in Japan and the Asia-Pacific region.
For pharmaceutical manufacturers and investors, SAKIGAKE designation offers strategic benefits in market positioning and commercial uptake. By facilitating earlier patient access through accelerated approval processes, the designation enables rapid market penetration and establishes first-mover advantages for designated drugs. This competitive positioning encourages pharmaceutical innovation and investment in Japan, drawing both multinational corporations and domestic companies to prioritize the Japanese market in their development plans.
From the perspective of patient care, SAKIGAKE designation leads to earlier access to innovative therapies for Japanese patients battling serious diseases and unmet medical needs. This expedited access can enhance clinical outcomes and improve the quality of life for patient populations previously lacking effective treatment options. The system reflects the PMDA's responsiveness to patient needs and its commitment to nurturing a dynamic pharmaceutical ecosystem.
For APAC investors and manufacturers, SAKIGAKE designation also has implications for manufacturing scale, biosimilar development, and cost-sensitive adoption strategies. As designated drugs enter the Japanese market more quickly, manufacturers must create efficient production and distribution networks to satisfy demand. Additionally, the designation may affect biosimilar development timelines and strategies, as companies look to capitalize on market opportunities created by innovative reference products approved through expedited pathways. Cost considerations remain pertinent, especially for manufacturers evaluating regional production hubs and supply chain optimization across APAC markets to meet Japan's pharmaceutical demand.
Future Outlook: Long-Term Impact on Innovation and Patient Care
The SAKIGAKE Designation System is likely to become increasingly significant in Japan's pharmaceutical ecosystem and its global competitiveness. Moving forward, the PMDA may expand eligibility criteria, integrate SAKIGAKE with other regulatory reforms, and align aspects of the designation with international expedited pathways, further enhancing Japan's appeal as a priority market for global pharmaceutical development.
The long-term effects of SAKIGAKE on patient care are expected to be substantial, with earlier access to innovative therapies becoming more standard for Japanese patients. This sustained improvement in access might set new benchmarks for clinical outcomes and quality of life across disease categories addressed by SAKIGAKE-designated drugs. Furthermore, the success of this designation could inspire other regulatory agencies in APAC to implement similar expedited pathways, fostering a more innovative and responsive pharmaceutical environment throughout the region.
For multinational and domestic pharmaceutical companies, SAKIGAKE designation will likely remain a key focus in Japan-centered development strategies. The incentive to pursue first-in-Japan approvals could lead to increased investment in Japan's pharmaceutical market, expanded clinical trial infrastructure, and enhanced regulatory collaboration with the PMDA. These collective advancements will support a more competitive and vibrant pharmaceutical ecosystem in Japan.
Frequently Asked Questions
What is the PMDA SAKIGAKE Designation System, and how does it differ from other expedited approval pathways?
The SAKIGAKE Designation System is a PMDA initiative initiated in 2015 (as a pilot) and formalized in September 2020 that accelerates the approval of innovative drugs with novel mechanisms targeting serious diseases with unmet medical needs. SAKIGAKE stands out from other expedited pathways, such as priority review and orphan drug designation, by requiring designated drugs to seek first approval in Japan, emphasizing novel mechanisms of action, and offering prioritized consultation throughout the development and review process. These unique features position SAKIGAKE as a distinct pathway within Japan's regulatory framework.
What are the eligibility criteria for SAKIGAKE designation?
To be eligible for SAKIGAKE designation, drugs must meet four key criteria: (1) demonstrate a novel mechanism of action not previously approved in Japan; (2) target serious diseases with documented unmet medical needs; (3) provide evidence of significant efficacy in clinical trials; and (4) pursue first approval in Japan. These criteria ensure that SAKIGAKE designation is reserved for truly innovative therapies addressing significant clinical gaps.
How many drugs have received SAKIGAKE designation, and in which therapeutic areas?
As of March 2020, eight drugs have been granted SAKIGAKE designation. These drugs span various therapeutic areas, including oncology, rare diseases, neurology, and immunology, highlighting the PMDA's commitment to innovation across diverse disease categories and patient populations.
What are the practical benefits of SAKIGAKE designation for pharmaceutical companies and patients?
For pharmaceutical companies, SAKIGAKE designation offers accelerated review timelines, prioritized consultation with PMDA reviewers during development, and a competitive first-mover advantage in the Japanese market. For patients, SAKIGAKE-designated drugs provide earlier access to innovative therapies addressing serious diseases with unmet medical needs, potentially enhancing clinical outcomes and quality of life. Additionally, the designation encourages pharmaceutical innovation and investment in Japan, supporting a dynamic and responsive pharmaceutical ecosystem.
How does SAKIGAKE designation compare to expedited approval programs in other major regulatory markets?
SAKIGAKE shares conceptual similarities with expedited pathways in other markets, such as the FDA's Breakthrough Therapy Designation in the United States and the European Medicines Agency's PRIME (Priority Medicines) program in Europe. However, SAKIGAKE's specific requirement for first approval in Japan sets it apart from these international pathways and reflects Japan's strategic aim to be a priority market for global pharmaceutical development. While each pathway balances expedited review with thorough evaluation of efficacy and safety, their specific criteria, timelines, and requirements differ based on regional regulatory priorities and public health considerations.
References
- Pharmaceuticals and Medical Devices Agency (PMDA). SAKIGAKE Designation System: Program Overview and Eligibility Criteria. Tokyo, Japan: PMDA; 2020.
Asia-Pacific Editor
Dr. Yuki Tanaka is an oncologist specializing in Asian pharmaceutical markets and regulatory harmonization. Former PMDA reviewer with expertise in bridging studies and ethnic factors....
About the Author
Related Articles
PMDA SAKIGAKE Designation: Expediting Innovative Drug Approvals in Japan
PMDA SAKIGAKE Designation: Accelerating Innovative Therapies in Japan
SAKIGAKE Designation Impact: Accelerating Rare Disease Drug Approvals in Japan
